Benjamin Graham Detailed Fundamental Analysis

Validea's analysis of Regeneron Pharmaceuticals (REGN) using Benjamin Graham's deep value model resulted in a 71% score, falling below the 80% threshold typically indicating 'some interest' for the strategy. While REGN passed key fundamental criteria such as sales, debt, and long-term EPS growth, it failed the strict valuation tests due to high P/E and Price/Book ratios, suggesting it does not align as a deep value investment despite strong operational metrics.

Analysis

Regeneron Pharmaceuticals (REGN) receives a score of 71% under Validea's investment model based on Benjamin Graham's deep value strategy, a rating that falls short of the 80% threshold typically required to indicate investor interest. The analysis reveals a significant divergence between the company's operational strength and its market valuation. REGN successfully passes fundamental criteria related to sales, liquidity (current ratio), and balance sheet health, as its long-term debt is well-covered by net current assets. Furthermore, it meets the requirement for solid long-term EPS growth. However, the stock fails on the two critical valuation metrics central to Graham's methodology: its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high. This profile suggests that while REGN is a fundamentally sound large-cap growth company, its current stock price does not offer the margin of safety sought by deep value investors, a conclusion reflected in the mildly negative sentiment score (-0.2).

Key Decisions for Investors

• Strict value investors following Graham's principles should exercise caution or avoid REGN at its current price, as it explicitly fails the core P/E and P/B valuation tests.
• Growth-oriented investors may find the positive signals in long-term EPS growth and strong fundamentals attractive, but must be comfortable paying a premium valuation that places it outside of value territory.
• For those with a hybrid or 'GARP' approach, REGN warrants being on a watchlist to potentially initiate a position during a significant market pullback that could bring its valuation multiples to more attractive levels.